Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2014-003973-41-FR
EUCTR2014-003973-41-FR
Active, not recruiting
Phase 1

A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic Shock

Ferring Pharmaceuticals A/S0 sites1,800 target enrollmentAugust 3, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsVasopressor-dependent Septic ShockMedDRA version: 18.0Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Vasopressor-dependent Septic Shock
Sponsor
Ferring Pharmaceuticals A/S
Enrollment
1800
Status
Active, not recruiting
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 3, 2015
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. 18 years of age or older.
  • •2\. Proven or suspected infection.
  • •3\. Septic shock defined as hypotension (systolic blood pressure less than 90 mmHg OR MAP less than 65 mmHg) requiring vasopressor treatment (i.e. any dose of norepinephrine / noradrenaline greater than 5 µg/min) despite adequate fluid resuscitation (at least one litre for hypotension).
  • •4\. Informed consent obtained in accordance with local regulations.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 900
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 900

Exclusion Criteria

  • •1\. Not possible to initiate IMP treatment within 12 hours from onset of vasopressor treatment for septic shock.
  • •2\. Primary cause of hypotension not due to sepsis (e.g. major trauma including traumatic brain injury, haemorrhage, burns, or congestive heart failure/cardiogenic shock).
  • •3\. Previous severe sepsis with ICU admission within this hospital stay.
  • •4\. Known/suspected acute mesenteric ischaemia.
  • •5\. Suspicion of concomitant acute coronary syndrome based on clinical symptoms and/or ECG during this episode of septic shock.
  • •6\. Chronic mechanical ventilation for any reason OR severe chronic obstructive pulmonary disease (COPD) requiring either continuous daily oxygen use during the preceding 30 days or mechanical ventilation (for acute exacerbation of COPD) during the preceding 30 days.
  • •7\. Received bone marrow transplant during the preceding 6 months or chemotherapy during the preceding 30 days for lymphoma or leukemia.
  • •8\. Known to be pregnant.
  • •9\. Decision to limit full care taken before obtaining informed consent.
  • •10\. Use of vasopressin in the past 12 hours prior to start of the IMP infusion or use of terlipressin within 7 days prior to start of the IMP infusion.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A controlled drug trial for 12 weeks plus another 4 weeks to test if Elobixibat 5 and 10 mg helps and is safe for patients with chronic constipatioChronic idiopathic constipationMedDRA version: 17.0Level: LLTClassification code 10072118Term: Chronic idiopathic constipationSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2012-005588-28-CZFerring International Pharmascience Center US, Inc.840
Active, not recruiting
Phase 1
A controlled drug trial for 26 weeks to test if Elobixibat 5 mg and 10 mg helps and is safe for patients with chronic constipatioChronic idiopathic constipationMedDRA version: 17.0Level: LLTClassification code 10072118Term: Chronic idiopathic constipationSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2012-005587-94-CZFerring International Pharmascience Center US, Inc.840
Active, not recruiting
Phase 1
A study to investigate the efficacy and safety of selepressin as treatment for patients with septic shock that need vasopressor treatmentVasopressor-dependent Septic ShockMedDRA version: 18.1Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2014-003973-41-NLFerring Pharmaceuticals A/S1,800
Active, not recruiting
Phase 1
A study to investigate the efficacy and safety of selepressin as treatment for patients with septic shock that need vasopressor treatment
EUCTR2014-003973-41-BEFerring Pharmaceuticals A/S868
Active, not recruiting
Not Applicable
A controlled drug trial for 12 weeks plus another 4 weeks to test if Elobixibat 5 and 10 mg helps and is safe for patients with chronic constipatioChronic idiopathic constipationMedDRA version: 16.1Level: LLTClassification code 10072118Term: Chronic idiopathic constipationSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2012-005588-28-PLFerring International Pharmascience Center US, Inc.840